[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].

R Tauber, J Gschwend, K Scheidhauer, M Eiber, M Krönke

Abstract read

In one paragraph

Article in Der Urologe. Ausg. A, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 99% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

R TauberKlinik und Poliklinik für Urologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland. r.tauber@tum.de.

J GschwendKlinik und Poliklinik für Urologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland.

K ScheidhauerInstitut für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.

M EiberInstitut für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.

M KrönkeInstitut für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, München, Deutschland.

Klinikum rechts der Isar · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radium-223 dichloride (Xofigo®, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment.

Indexed as

Bone NeoplasmsDose-Response Relationship, RadiationEvidence-Based MedicineHumansMaleProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRadiumSymptom AssessmentTreatment OutcomeRadioisotopesRadiopharmaceuticalsRadiumradium Ra 223 dichlorideAlpha ray therapyBone metastasesCastration-resistant prostate cancerNext generation hormonal treatmentRadionuclide therapyThrombocytopenia

Identifiers

PMID28058455

DOI10.1007/s00120-016-0300-5

OpenAlexW2576792938

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.